DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde


Krop I, Johnston S, Mayer IA et al.
The FERGI phase II study of the PI3 K inhibitor pictilisib (GDC-0941) plus fulvestrant vs. fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)- resistant advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium 2014; Abstract No. S2–02.

Download Bibliographical Data

Search in: